Literature DB >> 7581978

Molecular defects in thyroid carcinomas: role of the RET oncogene in thyroid neoplastic transformation.

M Santoro1, M Grieco, R M Melillo, A Fusco, G Vecchio.   

Abstract

Tumors are believed to arise as a result of an accumulation of mutations in critical genes involved in the control of cell proliferation. Thyroid neoplasms represent a good model for studying the role of these mutations in epithelial cell multistep carcinogenesis because they comprise a broad spectrum of lesions with different degrees of malignancy. Recent reports have described the involvement of specific genetic alterations in different types of thyroid neoplasms. Papillary carcinomas are characterized by the activation of the receptor tyrosine kinases RET and TRK-A proto-oncogenes. Ras point mutations are frequently observed in tumors with follicular histology and a high prevalence of p53 point mutations have been found in anaplastic carcinomas. A definition of molecular defects characterizing thyroid tumors will be helpful in establishing sensitive and specific detection strategies and, in addition, to define genetic and environmental factors important for their pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7581978     DOI: 10.1530/eje.0.1330513

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  10 in total

1.  Rat protein tyrosine phosphatase eta suppresses the neoplastic phenotype of retrovirally transformed thyroid cells through the stabilization of p27(Kip1).

Authors:  F Trapasso; R Iuliano; A Boccia; A Stella; R Visconti; P Bruni; G Baldassarre; M Santoro; G Viglietto; A Fusco
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

Review 2.  Multiple endocrine neoplasia syndromes, children, Hirschsprung's disease and RET.

Authors:  S W Moore; M G Zaahl
Journal:  Pediatr Surg Int       Date:  2008-03-26       Impact factor: 1.827

3.  Role of PTPRJ genotype in papillary thyroid carcinoma risk.

Authors:  Rodolfo Iuliano; Dario Palmieri; Huiling He; Angela Iervolino; Eleonora Borbone; Pierlorenzo Pallante; Alessandra Cianflone; Rebecca Nagy; Hansjuerg Alder; George A Calin; Francesco Trapasso; Carla Giordano; Carlo M Croce; Albert de la Chapelle; Alfredo Fusco
Journal:  Endocr Relat Cancer       Date:  2010-10-29       Impact factor: 5.678

4.  Inflammation in thyroid oncogenesis.

Authors:  Federica Liotti; Carla Visciano; Rosa Marina Melillo
Journal:  Am J Cancer Res       Date:  2012-04-21       Impact factor: 6.166

5.  Genetic Changes in Chromosomes 1p and 17p in Thyroid Cancer Progression.

Authors:  Celina G. Kleer; Bonita R. Bryant; Thomas J. Giordano; Mark Sobel; Maria J. Merino
Journal:  Endocr Pathol       Date:  2000       Impact factor: 3.943

6.  Papillary thyroid carcinoma oncogene (RET/PTC) alters the nuclear envelope and chromatin structure.

Authors:  A H Fischer; J A Bond; P Taysavang; O E Battles; D Wynford-Thomas
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

Review 7.  Adiponectin and Thyroid Cancer: Insight into the Association between Adiponectin and Obesity.

Authors:  Yuanyuan Zhou; Ying Yang; Taicheng Zhou; Bai Li; Zhanjian Wang
Journal:  Aging Dis       Date:  2021-04-01       Impact factor: 6.745

8.  Evaluation of Endocrine Neoplasms Using Fine Needle Aspiration Biopsy.

Authors:  Mary E. Barcus; Celeste N. Powers
Journal:  Endocr Pathol       Date:  2000       Impact factor: 4.056

9.  New treatment in advanced thyroid cancer.

Authors:  Dario Giuffrida; Angela Prestifilippo; Alessia Scarfia; Daniela Martino; Stefania Marchisotta
Journal:  J Oncol       Date:  2012-10-22       Impact factor: 4.375

Review 10.  The Hirschsprung's-multiple endocrine neoplasia connection.

Authors:  Sam W Moore; Monique Zaahl
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.